NeonMind Goes Public
Psychedelics biotech company NeonMind debuted on the Canadian Securities Exchange (CSE) Monday under the symbol ‘NEON.’
NeonMind CEO Penny White discussed the highly anticipated — oversubscribed — initial public offering (IPO) on the Jan. 7 edition of the Benzinga Cannabis Hour:
The company generated proceeds of about CA$4.6 million ($3.6 million).
“We are very excited about this next phase of growth for the company and have big plans for both our psilocybin research and medicinal mushroom products,” White said on the show.
In November 2020, NeonMind launched a line of non-psychedelic functional mushroom products available through its own ecommerce store.
NeonMind’s psychedelics research arm is focused on studying the possible applications of psilocybin in the treatment of eating disorders. So far, it filed five provisional patent applications claiming the use of psilocybin and other psychedelics as possible treatments.
The company is currently developing protocols for a phase II human clinical trial on the same subject, which it expects to present for approval in early 2021.
MAPS and Field Trip Team Up To Study MDMA In Eating Disorders
Field Trip Health's (PINK: FTRPF) Toronto clinic will serve as a trial location for MAPS’ upcoming study on MDMA-assisted therapy to treat eating disorders.
In July 2020, the Multidisciplinary Association for Psychedelic Studies announced a Phase 2 clinical trial, meant to assess the safety and feasibility of MDMA treatment in anorexia nervosa and binge eating disorder.
Field Trip’s Toronto location was selected as one …